Stockreport

Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease

Akebia Therapeutics, Inc.  (AKBA) 
Last akebia therapeutics, inc. earnings: 3/10 07:49 am Check Earnings Report
US:NASDAQ Investor Relations: ir.akebia.com/investor-relations
PDF Each Study Met Primary Endpoint at 24-Weeks and Showed Vadadustat’s Effect on Hemoglobin Was Sustained Through to 52-WeeksData Presented at the American Society of Nephr [Read more]